HONG KONG, Sept. 28, 2011 /PRNewswire-Asia-FirstCall/ --
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced that
the Company has filed with the U.S. Securities and Exchange
Commission its Annual Report on Form 20-F, which included audited
financial statements for the fiscal year ended March 31, 2011. The Form 20-F can be
accessed by visiting the U.S. Securities and Exchange Commission's
website at www.sec.gov and can also be found at the Investor
Relations Section of CCBC's website at
http://ir.chinacordbloodcorp.com. CCBC will provide a hard
copy of the Annual Report, including a complete set of audited
financial statements, free of charge to its shareholders upon
request.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood
banking operator in China in terms
of geographical coverage and is the only cord blood banking
operator with multiple licenses. Under current PRC government
regulations, only one licensed cord blood banking operator is
permitted to operate in each licensed region and only seven
licenses have been authorized as of today. China Cord Blood
Corporation provides cord blood collection, laboratory testing,
hematopoietic stem cell processing, and stem cell storage services.
For more information, please visit our website at
http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the
U.S. Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the Company, are expressly qualified by the
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. In addition, the Company
disclaims any obligation to update any forward-looking statements
to reflect events or circumstances after the date hereof.
For more information, please
contact:
|
|
|
|
China Cord Blood
Corporation
|
|
Ms. Joeling Law
|
|
Tel: (+852) 3605-8180
|
|
Email: ir@chinacordbloodcorp.com
|
|
|
|
ICR, Inc.
|
|
In New York: Ashley Ammon De
Simone: 1-646-277-1227
|
|
In Beijing: Wen Lei Zheng:
+86-10-6583-7510
|
|
|
SOURCE China Cord Blood Corporation